Although there is no assurance that the positive findings surrounding c‐Abl inhibition in animal models will translate into clinical benefits in PD patients, we believe, based on available data, it is important to test these new molecules in well controlled double‐blind trials to establish whether the promise of mechanistic understanding in models translates into meaningful benefits for PD patients. The gene discussed is ABL1; the disease is Parkinson disease.